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Summary
Over the last two decades a favourable course for treated or nontreated brainstem cavernomas has become possible with
enhanced diagnostic tools and clinical experience, as well as minimally invasive microsurgical improvements. Currently,
brainstem cavernoma can be treated microsurgically with excellent results and an acceptable morbidity rate. The preferred
surgical route has progressively shifted from a dorsal to a lateral approach, but this remains dependent on the location of
the lesion in the brainstem. Surgical evaluation and management of all cases of this rare disease should be performed by
experienced teams from the outset.
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Introduction
In recent decades the incidence of cerebral cavernous malformations (CCM) has increased due to diagnostic advances
with widespread use of magnetic resonance imaging (MRI) in clinical practice (prevalence 0.4–0.9%) [9, 24]. Brainstem
cavernomas account for 8–22% of all intracranial cavernomas [13]. This subgroup of CCMs has a substantially higher
propensity for bleeding (up to 30%) [21], is more likely to result in severe neurological deficits [7, 13, 21] and moreover
has a higher incidence of recurrent haemorrhage than those in other locations [22, 30]. Altogether, our experience with
brainstem cavernoma includes over 180 cases, most of them (130) being referred and treated microsurgically by the senior
author (HB). The remaining lesions were managed conservatively and regularly monitored by MRI. Here we briefly
summarise the literature and our experience in managing this disease.
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Figure 1
A 25 yo/f suffering from a right ponto-
mesencephalic cavernomal haemorrhage
(arrows) with subacute ataxia, hemiparesis
and facial palsy (A and B). The surgery was
performed on the left side via a combined
supracerebellar and retrosigmoid approach
(C). The arrows represent the approach to
the cavernoma. Postoperative MRI image in
T2 (D) revealed complete resection of the
cavernoma with residual haemosiderin from
the haemorrhages in the intact brainstem
tissue (arrow). Postoperatively, only a
temporary slight increase of ataxia was
noted and further follow-up showed almost
complete resolution of the preoperative
symptoms.
Clinical symptoms
The annual risk of brainstem cavernoma haemorrhage accounts for
3.8–6% per person/year and shows a remarkable 30~60% rehaemorrhage
rate per person/year [22, 30]. The extent of persistent neurological deficits
correlates with the number of recurrent haemorrhages, and rebleeding
episodes tend to occur at progressively shorter time intervals [22].
Haemorrhage from a brainstem cavernoma can be fatal in 20% of cases
[7, 13, 22]. Neurological deficits depend greatly on the localisation of the
lesion and vary significantly, including various degrees of internuclear
ophthalmoplegia, worsening hemiparesis, facial or abducens paresis, gaze
palsy, facial, truncal and extremity numbness, dysphagia, dysarthria, and
gait ataxia, among others [2, 13, 22]. The clinical symptoms usually
appear in a subacute manner over hours or days, and most cases are
treated temporarily with dexamethasone to avoid malignant swelling of
the brainstem and secondary problems. Acute incidents with loss of
consciousness or breathing disability occur very rarely.
Imaging
The gold standard for visualisation of the anatomical as well as
pathological findings, such as the extent of the lesion and haemorrhage, is
MRI. High field (1,5 or 3,0 Tesla) images with T1 (with and without
contrast enhancement), T2 and gradient echo sequences in all three planes
(axial, coronal, sagittal) are critical for guidance of all decisions.
Additional tools such as T2-based imaging and fibre tracking have further
improved the visualisation and understanding of these lesions [6].
Surgical treatment
Indications, goal and timing of surgery
Expert opinion varies regarding the indication and timing of surgery, but
if haemorrhage appears associated with worsening of the neurological
deficit surgical evacuation of the lesion and haematoma is recommended
(fig. 3) [28]. Exceptionally, surgery for even asymptomatic patients is also
proposed [27]. As a general rule clinical symptoms should be the main
indication for surgery, and the patient option should preferably also be
included in the decision process (fig. 3). The main goal of surgery is
eliminating the risk of renewed haemorrhage and avoiding complications [1, 2, 22, 30]. Hence complete removal of the
lesion is essential to prevent re-haemorrhage, which may occur in up to 43% of surgical cases [5]. However, in our
brainstem cavernoma series we found a postoperative rebleeding rate of 4.4%. The risk of leaving residual portions of the
lesion behind depends on surgeon experience. The larger the series, the lower the incidence of residuals [22, 30]. In the
past two decades, waiting four to six weeks after a haemorrhagic event was recommended to stabilise the patient’s
condition and waiting for the haematoma to become organised to achieve less active gliosis [10]. However, the incidence
of rebleedings is highest within one month after surgery (21.8%) [22]. Prior to surgery, treatment with steroids for one or
two weeks is recommended to resolve oedema and take advantage of haematoma cavity formation [30].
Surgical approaches to the brainstem and intraoperative monitoring
A great variety of surgical approaches, such as the suboccipital midline, retrosigmoid or subtemporal approaches exist in
many instances of brainstem cavernoma [5, 8, 10, 16, 17, 22, 23, 30]. The choice of the proper approach depends on the
relationship between the cavernoma and the pial or ependymal surface of the brainstem. As the floor of the fourth
ventricle contains structures with important functions [3, 23], a lateral entry is preferred whenever possible. The
supracerebellar infratentorial approach (fig. 1) is suitable for many lesions and has yielded favourable patient outcomes; it
is one of our preferred access routes. Intraoperative electrophysiological monitoring of long tracks (MEP and SEP), AEP
and cranial nerves is obligatory during brainstem surgery [2, 25].
Complications, morbidity and mortality
Postoperative morbidity may be due to manipulation or oedema of brainstem parenchyma, and permanent morbidity was
reported earlier in the range of 12% ~21% [12, 22, 26, 30]. However, the morbidity rate is clearly related to surgical
experience [1, 2].
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Figure 3
Flowchart to differentiate between
nonsurgical versus surgical management in
patients with brainstem cavernomas.
Figure 2
Left MRI images (A) show a typical mesencephalic cavernoma haemorrhage on the left side (arrows) in
an axial T1 (no gadolinium-DTPA) and coronal T1 (with gadolinium-DTPA). The patient suffered from a
slight headache and partial hemi-hypoaesthesia. Surgery in this case was not advised. The MRI images
2 months later (B) showed resorption of the acute haemorrhage with no sign of residual cavernoma
(arrows). The MRI images after one year (C) confirmed the positive follow-up with complete resolution of
all symptoms. The upper axial T1 (with gadolinium-DTPA) demonstrates again the old lesion with no sign
of recurrence. The lower axial MRI image is a special sequence (gradient echo) to detect haemosiderin
in the brain. It shows the old lesion and status after haemorrhage, which should not be mistaken for a
new haemorrhage.
Alternative treatments
Stereotactic radiosurgery
The use of radiosurgery for cavernomas has remained controversial, since
the main goal of radiosurgery should be a significant reduction in
bleeding risk. Some authors have insisted on the efficacy of radiosurgery
for intracranial cavernomas, due to the reduced risk of haemorrhage after
a latency period of 2 years [14, 15, 19]. However, the annual risk of
haemorrhage during the latency period after radiosurgery is greater than
10% [15]. In our opinion stereotactic radiosurgery should not be
considered as the first-step treatment for intracranial or brainstem
cavernoma, since it fails to eliminate the risk of haemorrhage.
If radiosurgery is adopted as the treatment modality of choice, accurate
evaluation in a neurosurgical centre should be considered since not every
so-called “surgically untreatable” lesion is surgically inaccessible [2, 29].
For instance, in their recently published serial Lunsford et al. presented a
figure of a cerebellar cavernoma which is surgically accessible in
experienced hands [20].
Conservative management
Long-term outcomes may be worse in a nonsurgical group (42% poorer
outcome) than in surgically treated patients (9%) [22]. But conservative
treatment plays an important role in patients with small lesions, rapid
clinical improvement after bleeding episodes and a nonaggressive
appearance of the lesion on MRI (fig. 2). In such cases it is important to
inform the patient of the estimated individual bleeding risk and, additionally, all treatment options and possible
morbidities should be discussed in detail. Nevertheless, mortality may occur whatever the decision [7, 13, 22]. We have
followed conservatively more than 50 patients with either initially minor or nonhaemorrhaging (incidental findings)
lesions. None of these patients has ever suffered life-threatening bleeding.
Follow-up and further management
We perform an initial MRI postoperatively or days after the first haemorrhage, and a follow-up MRI 2–3 months
afterwards. Yearly MRI should be considered for all patients with or without surgery, and should be performed in a
neurosurgically experienced centre.
Genetics and research
Some research groups have focused on the biological behaviour of cerebral cavernous malformations despite the rarity of
this disease. Recent work has uncovered the association of three mutations CCM1 (KRIT1), CCM2 (MGC4607) and
CCM3 (PDCD10) [11], PTEN promoter methylation [32] and disease modulating factors such as the HEG
transmembrane receptor [18] and the RhoA GTPase [31] with this disease. Further research will aim to elucidate the
pathogenesis of cavernomas in terms of cellular mechanisms of pathological angiogenesis [4] and de novo mutations,
with a view to defining specific targets for future therapeutic interventions. Better genetic knowledge will also improve
genetic counselling, which is recommended in familial cases [11].
Conclusion
Modern treatment options for brainstem cavernomas include a variety of diagnostic and surgical tools, experience and
dedication. Altogether, favourable outcomes can be achieved and surgically nontreatable lesions are extremely rare. The
most important factor is involvement of a surgically experienced clinic at the beginning of the diagnosis.
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